FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
